193 related articles for article (PubMed ID: 32908944)
1. Outcomes of Outpatient Parenteral Antimicrobial Therapy With Ceftriaxone for Methicillin-Susceptible
Hamad Y; Connor L; Bailey TC; George IA
Open Forum Infect Dis; 2020 Sep; 7(9):ofaa341. PubMed ID: 32908944
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Ceftriaxone Compared With Cefazolin or Nafcillin/Oxacillin for Outpatient Therapy for Methicillin-Sensitive
Hamad Y; Nickel KB; Olsen MA; George IA
Open Forum Infect Dis; 2024 Feb; 11(2):ofad662. PubMed ID: 38352150
[TBL] [Abstract][Full Text] [Related]
3. Safety and Efficacy of Ceftriaxone in the Treatment of Methicillin-Susceptible
Ganguly A; de la Flor C; Alvarez K; Brown LS; Mang NS; Smartt J; King H; Perl TM; Filizola H; Bhavan KP
Ann Pharmacother; 2023 Apr; 57(4):425-431. PubMed ID: 35942602
[TBL] [Abstract][Full Text] [Related]
4. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia.
Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065
[TBL] [Abstract][Full Text] [Related]
5. Comparative outcomes of β-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches.
Lee B; Tam I; Weigel B; Breeze JL; Paulus JK; Nelson J; Allison GM
J Antimicrob Chemother; 2015 Aug; 70(8):2389-96. PubMed ID: 26024869
[TBL] [Abstract][Full Text] [Related]
6. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and Safety of Ceftriaxone Compared to Standard of Care for Treatment of Bloodstream Infections Due to Methicillin-Susceptible
Alsowaida YS; Benitez G; Bin Saleh K; Almangour TA; Shehadeh F; Mylonakis E
Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326838
[TBL] [Abstract][Full Text] [Related]
8. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of Cefazolin Versus Ceftriaxone for the Treatment of Methicillin-Susceptible
Carr DR; Stiefel U; Bonomo RA; Burant CJ; Sims SV
Open Forum Infect Dis; 2018 May; 5(5):ofy089. PubMed ID: 30568987
[TBL] [Abstract][Full Text] [Related]
10. Clinical Outcomes of an Innovative Cefazolin Delivery Program for MSSA Infections in OPAT.
Herrera-Hidalgo L; Luque-Márquez R; de Alarcon A; Guisado-Gil AB; Gutierrez-Gutierrez B; Navarro-Amuedo MD; Praena-Segovia J; Carmona-Caballero JM; Fraile-Ramos E; Gutierrez-Valencia A; Lopez-Cortes LE; Gil-Navarro MV
J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329878
[TBL] [Abstract][Full Text] [Related]
11. Outpatient parenteral antimicrobial therapy for the treatment of methicillin-susceptible Staphylococcus aureus: a comparison of cefazolin and ceftriaxone.
Winans SA; Luce AM; Hasbun R
Infection; 2013 Aug; 41(4):769-74. PubMed ID: 23686435
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible
Beganovic M; Cusumano JA; Lopes V; LaPlante KL; Caffrey AR
Open Forum Infect Dis; 2019 Jul; 6(7):ofz270. PubMed ID: 31281864
[TBL] [Abstract][Full Text] [Related]
13. Twice daily cefazolin is effective for treatment of serious methicillin-sensitive
Birrell MT; Fuller A
Ther Adv Infect Dis; 2019; 6():2049936119882847. PubMed ID: 31839941
[TBL] [Abstract][Full Text] [Related]
14. Role of outpatient parenteral antibiotic therapy in the treatment of community acquired skin and soft tissue infections in Singapore.
Chan M; Ooi CK; Wong J; Zhong L; Lye D
BMC Infect Dis; 2017 Jul; 17(1):474. PubMed ID: 28683717
[TBL] [Abstract][Full Text] [Related]
15. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.
Li J; Echevarria KL; Hughes DW; Cadena JA; Bowling JE; Lewis JS
Antimicrob Agents Chemother; 2014 Sep; 58(9):5117-24. PubMed ID: 24936596
[TBL] [Abstract][Full Text] [Related]
16. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML
Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314
[TBL] [Abstract][Full Text] [Related]
17. Ceftriaxone for the Treatment of Methicillin-susceptible
Lowe RA; Barber KE; Wagner JL; Bell-Harlan AM; Stover KR
J Pharmacol Pharmacother; 2017; 8(3):140-144. PubMed ID: 29081626
[TBL] [Abstract][Full Text] [Related]
18. Daptomycin Plus Oxacillin for Persistent Methicillin-Susceptible
Kufel WD; Zagoria Z; Blaine BE; Steele JM; Mahapatra R; Paolino KM; Thomas SJ
Ann Pharmacother; 2024 Apr; 58(4):360-365. PubMed ID: 37542415
[TBL] [Abstract][Full Text] [Related]
19. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.
Wieland BW; Marcantoni JR; Bommarito KM; Warren DK; Marschall J
Clin Infect Dis; 2012 Mar; 54(5):585-90. PubMed ID: 22144536
[TBL] [Abstract][Full Text] [Related]
20. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
